Takeda’s Ninlaro Misses Mark In Transplant-Ineligible 1L Myeloma
Executive Summary
Oral proteasome inhibitor fails to reach significance when added to standard combination therapy in first-line myeloma patients who cannot receive marrow transplants, but development continues in other settings.
You may also be interested in...
Ninlaro Positive In Non-Transplant MM Maintenance
Following a failure in a different indication earlier this year, positive top-line results show promise for Takeda proteasome inhibitor positive in first-line myeloma maintenance in non-transplant patients, setting the path for approval filings.
Ninlaro Looking Positive In MM Maintenance On Back Of TOURMALINE Data
Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.